At the start of this week, the focus was on Fractyl Health’s first earnings post-IPO and the company’s wide stock swings. Fractyl continued to share news later in the week, including a new executive appointment. Read more about Fractyl and other big biotech news from this week.
Source link
Petri Dish: Vertex kidney drug moves into Ph 3; Fractyl preps for commercialization
